Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 1.00 |
| ▸ | HTR2B | P41595 | 7/20 | 1.00 |
| ▸ | HTR2A | P28223 | 7/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411291 | 0.83 | HTR2C (0.76) | HTR2CHTR2BHTR2A | |
| SCHEMBL6408932 | 0.82 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL6629013 | 0.80 | HTR2C (0.66) | HTR2CHTR2BHTR2AKCNH2 | |
| SCHEMBL467105 | 0.74 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| SCHEMBL6408467 | 0.73 | HTR2A (0.58) | HTR2CHTR2BHTR2ASIGMAR1KCNH2 | |
| Hydrochloric Acid SCHEMBL1895959 | 0.73 | SIGMAR1 (0.98) | SIGMAR1KCNH2 | |
| SCHEMBL467006 | 0.72 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| SCHEMBL4899236 | 0.72 | HTR2C (0.56) | HTR2CHTR2BHTR2AKCNH2 | |
| SCHEMBL466940 | 0.72 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| SCHEMBL28114577 | 0.72 | KCNH2 (0.94) | SIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | claimed |
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | claimed |
| US-RE45173-E1 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-8263635-B2 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | disclosed |
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | HTR2C, HTR3C, HTR5A | HTR2C 1/4885HTR2B 28/4885HTR2A 30/4885 |
| US-20100331326-A1 | Inhibitors of CYP 17 | CYP17A1, CYP21A2, CYP4A22 | HTR2C 1382/4885HTR2B 1585/4885HTR2A 3119/4885 |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | CYP17A1, CYP21A2, CYP4A22 | HTR2C 1382/4885HTR2B 1585/4885HTR2A 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.